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ABSTRACT
A rising number of long-term survivors and potential long-term outcome related to the treatment is
one of the most important issue due to the advances of management in cancer. The development of
secondary malignancy has been reported in a number of cohorts. We present a case of breast cancer
patient developing acute myeloid leukemia (AML)- M5 within a relatively short interval of two and a
half years from her primary treatment with adjuvant chemotherapy with 4 cycles of doxorubicin and
cyclophosphamide, followed by 4 cycles of three weekly paclitaxel (AC-T)  and radiotherapy. What
could be attributed to the occurrence of secondary leukemia in this patient will be discussed.
ABSTRAK
Kondisi klinis yang dialami dalam jangka waktu panjang oleh seseorang penderita kanker yang telah
berhasil melewati jangka waktu lama setelah terdiagnosis (long term-survivor) merupakan hal penting
yang harus diperhatikan karena jumlah yang semakin meningkat. Hal ini tentu tidak terlepas dari
berbagai kemajuan dalam penatalaksanaan kanker. Perkembangan keganasan sekunder merupakan
salah satu hal yang sering dilaporkan. Kami melaporkan kasus seorang penderita kanker payudara
yang berkembang menjadi leukemia mieloid akut tipe M5 dalam jangka waktu yang relatif pendek
yakni 2,5 tahun setelah pasien menyelesaikan kemoterapi ajuvan sebanyak 4 siklus dengan doxorubicin
dan cyclophosphamide, diikuti 4 siklus paclitaxel tiga mingguan (AC-T) dan radioterapi. Hal-hal apa
saja yang mungkin berperan dalam kejadian keganasan berupa leukemia sekunder pada pasien ini
akan dibahas dalam laporan kasus ini.
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INTRODUCTION
Despite the high incidence of breast cancer
(BC), the mortality rate is declining. This might
be related to advances in the better diagnostics
and treatment modalities.1,2  Consequently, there
is a rising number of long-term survivors and
increasing attention must be focused on the
potential long-term outcome related to the
treatment that could affect the overall quality of
patient survival. Among the potential long-term
effect of cytotoxic agents used to treat breast
cancer, the development of secondary leukemia
(SL) has been evaluated in a number of different
cohorts of patients.3 Possible causal relationship
between the prior chemotherapy, radiotherapy,
combined chemotherapy and radiotherapy, and
the occurrence of SL in BC had also been
proposed.4
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CASE PRESENTATION
A female, 50 years old, was diagnosed with
cancer of left breast in June 17th, 2008. She
started to notice a small lump in her left breast
in June 2008 before then she proceeded to
have a mammography which confirmed a
suspicious abnormality Breast Imaging
Reporting and Data System (BI-RADS 4). A fine
needle aspiration was done with result of
positive for malignant cells. A modified radical
mastectomy was performed. Pathology of the
tumor was infiltrative ductal carcinoma grade
II metastasis to one of three regional nodes.
Estrogen and progesterone receptors were
positive, c-erbB2 (Her2Neu) was found to be
negative by immunohistochemistry. She was
treated with adjuvant chemotherapy of 4 cycles
of doxorubicin 60mg/m2 and cyclophospamide
600mg/m2, followed by three weekly paclitaxel
175mg/m2. The doses based on her body
surface area were doxorubicin 100mg and
cyclophosphamide 1.000mg given in every 3
weeks for 4 cycles. The following paclitaxel dose
was 300mg for each cycle given in every 3 weeks
for 4 cycles. The cumulative doses of drugs
administered were doxorubicin 400mg,
cyclophosphamide 4.000mg and paclitaxel 1.200mg.
She did not need any support for granulocyte
stimulating factors during her chemotherapy courses.
After completion of chemotherapy series over 5
weeks, she received radiotherapy for a total dose
of 52 Gray in 26 fractions by Cobalt-60 completed
on March 4th, 2009. Tamoxifen 20mg daily was
also started to be given for 5 years.
She had been in good condition and had no
FIGURE 1. a) Peripheral blood smear, b). Bone marrow smear stained by May Gruenwald Giemsa, c). Bone marrow
smear: fine granules of the monoblasts were stained by PAS, d). Bone marrow smear: granules of the
myeloblasts and monoblasts were stained strongly and weakly respectively by SBB
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abnormal laboratory results until August 2nd, 2011
when she visited in the outpatient clinic with
complaints of fever, sore throat and mouth, bone
pain and non-productive cough in the last 2 weeks.
A complete blood count revealed her leukocyte
count of 160x109/L, hemoglobin level of 9.9gr/dL,
and platelet count of 74x109/L. A peripheral blood
smear showed leukocytosis with 72% blast
resembling myeloid cells accompanied with
normocytic normochromic anemia and thrombocyto-
penia. A bone marrow punction was done on the
sternum showing result of an increase in myeloid seri
with 61% myeloblast and 15% monoblast. Fine
granules of the monoblasts were stained by
periodic acid Schiff (PAS). Granules of the
myeloblasts and monoblasts were stained strongly
and weakly respectively by sudan black blue
(SBB), confirming the diagnosis of AML-M4
(FIGURE 1). A cytogenetic analysis showed a
normal karyotype (FIGURE 2). She expired two
days after the diagnosis of acute leukemia, before
induction treatment was commenced. She died in
a sudden death during her visit to the out patient clinic,
on August 11th, 2011, possibly due to leukostasis
syndrome. Her last blood count showed leukocyte
count of 213.3x109/L, hemoglobin level of 9.1gr/dL,
and platelet count of 51x109/L.
FIGURE 2. Cytogenetic analysis showed a normal karyotype
DISCUSSION
Prolonged survival in breast cancer patients
Breast cancer is the most frequently diagnosed
cancer among women in most developed countries
and accounted for about one-third (n = 207.090)
of all new cancer cases in U.S. women in 2010.5
Survival after a diagnosis of BC has steadily
improved, due largely to earlier detection and the
application of effective treatment regimens, thus,
given a current 5- year relative survival rate of
almost 90%.5 The improvement of survival rate in
BC is due to the contribution of significant progress
in the management of BC including better
chemotherapy and radiation treatment options
and guidelines based on diagnostic tumor
characteristics.3 As of January 2008, it is estimated
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that there are 11.9 million cancer survivors which
represented approximately 4% of the population,
among which women with BC are the most
common survivors.6 This burgeoning number
underscores the importance of quantifying late
adverse effects of cancer therapy, which can
influence cancer treatment practices and patient
survival.
Incidence of secondary AML in BC
Secondary non-breast cancer (SNBC)
including secondary hematologic malignancy
(SHM) particularly acute myeloid leukemia
(AML) and myelodysplastic syndrome (MDS)
are among several potential long-term adverse
events associated with adjuvant chemotherapy
in breast cancer which have been described.
Moreover, cardiac toxicity, cognitive function,
neurotoxicity and problem related with
reproductive problems and sexuality were also
described.7 It is estimated that 1 in every 20
patients will develop an SNBC in 10 years after
diagnosis of breast cancer, which corresponds
to a 22% increase in the relative risk.8
Therapy related acute myeloid leukemia or
myelodysplastic syndromes (t-AML/MDS) are
collectively known as therapy-related myeloid
neoplasms (t-MN) included among “Acute
myeloid leukemias and precursor neoplasms”
in the 2008 WHO classification. The term
“therapy-related” leukemia is descriptive and
based on patient’s history of exposure to
cytotoxic agents. The latency between primary
diagnosis and therapy-related disease ranges
from few months to several years, with a median
of about two years, depending on several
factors. Beside therapy-related forms, there are
AML/MDS defined as “second malignancy”
arising as second cancer after a previous
diagnosis of a neoplasm treated with surgery
alone or without any exposure to any systemic
therapy.9
Yu et al.10 reported an increase in incidence
of secondary leukemia in BC patients by about
300% from 8 per 100.000 person-years in the
1970s to 32 per 100.000 person-years in the
1990s among young patients aged 20-49. A
registry cohort analysis from 1990-2005
including 5.790 BC patients reported 17
incident cases of MDS with 10 MDS and 7
AML with median time from BC to MDS/AML
diagnosis was 4.35 years and median time from
radiation or chemotherapy was 3.06 years.3
In this case, AML-M5 was diagnosed at 3
years after the initial diagnosis of breast cancer,
and at 2.5 years post treatment by adjuvant
chemotherapy and radiation.
Adjuvant chemotherapy and Secondary
leukemia
During the past few decades, we have
witnessed a paradigm shift of BC treatment,
moving from classic CMF (cyclophosphamide,
methotrexate, and 5-fluorouracil) to
anthracycline-based regimens, to the subsequent
incorporation of taxanes, administration of
dose-dense regimens, and, most recently, the use
of biological agents.11 Secondary leukemia risk
has been evaluated in many studies of commonly
used alkylating agents and anthracyclines.
The antineoplastic activity of alkylating
agents is related to their ability to damage
Deoxyribonucleade Acid (DNA) by methylation
or DNA inter-strand crosslinks formation,
interfering with normal DNA replication. Of the
commonly used alkylating agents, melphalan is
highly leukemogenic, while cyclophosphamide
is graded at a lower scale, possibly on account
of it’s relatively stem cell sparing effect.
Alkylating agent-related AML typically
develops after an average latency of 5-7 years,
and overt leukemia is often (up to 70% of cases)
proceeded by a dysplastic phase.7 Fisher et al
reported that the 10-year cumulative risk of
AML was increased in BC patients treated with
surgery followed by melphalan based
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chemotherapy compared to those treated with
surgery alone (1.29% versus 0.27%,
respectively).12 In the following years the
leukemogenic potential of cyclophosphamide
has emerged. A combined analysis of six
adjuvant studies conducted by the National
Surgical Adjuvant Breast and Bowel Project
group involving 8,536 patients using
cyclophosphamide and doxorubicin (AC)
reported a 5-year incidence of AML ranging
from 0.3% to 1.2%. Higher risk was associated
with greater dose intensity of AC requiring G-
CSF support. Breast radiotherapy also appeared
to be associated with an increased risk of AML/
MDS.13
The latency period between exposure to
anthracyclines and the onset of leukemia is
usually about 2 years, and generally there is no
previous myelodysplastic phase. The Epirubicin
Monitoring Plan is the most comprehensive
analysis of secondary leukemia after treatment
with adjuvant epirubicin completed to date, with
9.796 patients observed for a total of 53.080
patients. The analysis confirms a small but
significant risk of AML/MDS in patients treated
with adjuvant epirubicin and cyclophosphamide
for early breast cancer. In all of the 7.110
patients treated with epirubicin-containing
regimens, the 8-year cumulative probability of
AML/MDS was 0.55%. The risk of developing
AML/MDS increased in relation to total dose
of epirubicin and total dose of
cyclophosphamide, with a steep increase at
cumulative doses above those used in
recommended regimens for adjuvant therapy
(epirubicin up to 720 mg/m2 and cyclo-
phosphamide up to 6.300 mg/m2). The highest risk
(4.97% cumulative probability at 8 years) was
seen in patients who had been administered
greater than standard doses of both epirubicin
and cyclophosphamide.14
Antineoplastic activity of taxanes appears to
be related to their ability to promote microtubular
E, epirubicin; C, cyclophosphamide; AC, doxorubicin and cyclophosphamide; CEF,
cyclo-phosphamide, epirubicin, and 5-fluorouracil; EC-P, epirubicin, cyclophosphamide,
and paclitaxel; Q2W, once every 2 weeks.
assembly and to inhibit microtubular disassembly.
A 7-year update of a study (1.016 subjects with
operable stage I to III invasive BC) comparing
AC with TC showed no secondary leukemia in
the TC arm, when compared with 2 of 510 cases
(0.4%) in the AC arm. Leukemia and
myelodysplasia are major anthracycline related
toxicities in women with breast cancer treated with
anthracyclines and another reason for considering
nonanthracycline regimens. Because there were
TABLE 1. The incidence of AML/MDS in BC following adjuvant chemotherapy
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only two cases in this study, no attempt was
made to look for the use of adjuvant radiation
therapy as a contributing factor.15 A three-arm
study comparing the Canadian CEF with 2-
weekly dose-dense EC followed by T and with
3-weekly AC followed by T showed that 0.5%
of patients developed AML in the first two arms.
This is mainly attributed to the high cumulative
dose of epirubicin and perhaps the use of G-
CSF to support chemotherapy. However, no
secondary leukemia was diagnosed in patients
randomly assigned to the AC-T arm.16 TABLE
1 shows the incidence of AML/MDS in BC
following adjuvant chemotherapy with various
regiments.
In this case, the patient was treated with
adjuvant chemotherapy of 4 cycles of
doxorubicin and cyclophospamide, followed by
3 weekly paclitaxel. The doses based on her
body surface area were- doxorubicin 100mg
and cyclophosphamide 1,000mg given in every
3 weeks for 4 cycles. The following paclitaxel
dose was 300mg for each cycle given in every
3 weeks for 4 cycles. The cumulative doses of
drugs administered were doxorubicin 400mg,
cyclophosphamide 4.000mg and paclitaxel
1.200 mg. This dose is much lower than the
maximum cumulative dose for cyclophos-
phamide shown to be related with the increased
incidence of secondary AML/MDS.13 Regarding
taxane, two studies failed to show the attribution
of paclitaxel in the incidence of secondary
AML/MDS after adjuvant treatment by taxane
combination.15,16
Role of Granulocyte Colony-Stimulating
Factors (G-CSF)
Administration of granulocyte stimulating
factors in women receiving adjuvant
chemotherapy for BC is aimed to reduce the
myelosuppressive effects of dose intense
chemotherapy. An analysis of the Surveillance,
Epidemiology, and End Realis (SEER)
medicare population-based database including
5.510 women with BC treated with adjuvant
chemotherapy, found that the addition of G-CSF
is associated with a doubling of the risk of
subsequent AML or MDS when compared with
chemotherapy alone, even if the absolute risk
is low.17 In the analysis of six trials described
by Smith et al.13 in 2003, the incidence of
therapy-related leukemia was sharply elevated
in patients treated with intensified regimens that
required G-CSF support (relative risk 6.16;
p=0.0001). Finally, a systematic review of 25
randomized clinical trials was recently
conducted to evaluate the risk of AML or MDS
in patients receiving chemotherapy for solid
malignancies and lymphomas with or without
the addition of G-CSF. At a median follow up
of 54 months, the estimated relative risk for
AML/MDS with G-CSF-supported chemo-
therapy was 1.92, with an estimate absolute
increase in risk of 0.4%.18 However, as relative
dose intensity (RDI) was also reported to be
higher in patients with growth factor support,
the authors concluded that it was not possible
to distinguish between the effects of G-CSF and
the effects of a higher delivered dose of
leukaemogenic chemotherapy agents.
In this case, the patient never had any
supports of G-CSF during the courses of
chemotherapy with sequential AC-T.
Radiotherapy and secondary leukemia
Radiotherapy may also play a significant
role in SL occurrence in BC patients. Several
studies report higher risk of leukemia in BC
patients given combined modality treatment
compared to chemotherapy or radiotherapy
alone.19,20 The radiation-related risk of
secondary leukemia was about 2.4 in patients
who were not treated with chemotherapy,
compared to 17.4 in patients who were treated
with both radiation and chemotherapy.19 In
another study, the risk of developing AML was
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increased by fourfold when radiotherapy
treatment was received (HR = 4.0; 95%
CI=1.4–11.8) and increased by sevenfold when
radiotherapy was combined with chemotherapy
treatment (HR = 7.2; 95%CI=1.4–36.3).21 A
cohort study analyzing clinical records of BC
patients with the aim of evaluating the long-term
effect of radiotherapy on the risk of second
cancers reported a total of 387 malignancies
(7.3%) in 5248 women, with eight patients
developing leukemia (0.15%), seven in the
group treated with radiotherapy, versus one case
only in the group not receiving radiotherapy.
The relative risk adjusted for chemotherapy and
hormone treatment was 6.67 (95% CI= 0.76-
58.00) and the median time from exposure was
4.5 years, with the suggestion of a raised
incidence of leukemia within the first two or
more years after radiotherapy.22
In our patient, she received radiotherapy
for a total dose of 52 Gray in 26 fractions by
cobalt-60 after the completion of AC-T courses.
Secondary AML in this patient was diagnosed
at 2.5years later after the completion of
radiotherapy. Since the risk of chemotherapy
alone was not markedly increased in this case
as the cumulative dose of the cyclophosphamide
being less than the maximum cumulative dose
shown to be related with the increased incidence
of secondary AML/MDS.13 The left possible
reason though not clearly ascertainable could
be the synergistic effect of radiation and
chemotherapy.
Genetic factors
Acute myeloid leukemia develops as a
result of acquired, non-random somatic
mutations in hematopoietic progenitor cells.
These mutations are found in the majority of
cases, with higher frequencies seen in leukemia
attributed to chemotherapy and advancing age.
Reports of a short time course to MDS and
AML, and a recent study of GCSF use in BC
support the possibility that treatment accelerates
the development of molecular events in cells
predestined to progress to AML. In support of
this theory, an association of treatment-related
leukemia with a polymorphism in the gene for
CYP3A4, an enzyme that metabolizes many
chemotherapeutic agents, has been described.23
On the other hand, it has been shown that
Secondary Hematological Malignancies (SHM)
can develop even in BC patients who were
treated with surgery alone.  For these patients
it may be hypothesized that secondary AML
develops after a previous BC because of a
genetic predisposition to neoplastic processes.24
Some of this risk is related to genetic
predisposition (BRCA2 and p53 carriers).25 A
study to further explore a genetic link for SHM
following BC, the impact of a positive family
history for breast/ovarian cancer on the risk of
SHM following BC has been done and
concluded that among BC patients, family
history was independently associated with the
development of leukemia.26
AML subtype and chromosomal aberration
in secondary AML in BC
Alkylating agent-related AML has been
frequently described as being either M1 or M2
according to french American Britih (FAB)
classification. Karyotypic analysis shows
alterations of chromosomes 5 and 7 in 60% to
90% of cases. The most common cytogenetic
findings are losses of chromosomes 5 or 7 and
deletions at 7q. A cytogenetic study including
14 patients with secondary AML with prior
treatment for BC with alkylating agents reported
that chromosomes 7, 5, 17, and 11 are
recurrently involved in numerical or structural
anomalies. They also reported 2 cases with normal
karyotype.27
AML/MDS associated with topoisomerase
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II inhibitor (doxorubicin, epipodophyllotoxin)
treatment present as either FAB M4 or M5 and
are frequently associated with translocation of
the long arm of chromosome 11 (11q23)
involving mixed-lineage leukemia (MLL) gene.
These translocations of the MLL gene result in
its fusion with a variety of partner genes
resulting in abnormal gene expression in
hematopoietic stem cells and subsequent
development of leukemia. Other abnormalities
including MLL partial tandem duplication, MLL
amplification, core binding factor (CBF)
translocations [namely t (8;21) and inv(16)], and
PML-Retinoic Acid Receptor Alpha (PML-
RAR-α) translocations have also been
described in therapy-related leukemia.
Refractory Anemia with Excess Blasts (RAEB)
and Refractory Anemia with Excess Blasts  in
Transformation (RAEB-t) have been found to
be the most common types of chemotherapy-
induced MDS.13 The addition of radiotherapy
appears to modulate susceptibility to cytogenetic
aberrations and is more often associated with
deletions or unbalanced mutations.25 In this case,
the analysis of chromosome did not reveal any
chromosomal aberrations.
CONCLUSION
Based on the subtype of AML-M5 and its
early occurrence at two and half years from her
primary treatment, we may suggest that it may
be related to the treatment given although the
chromosomal data did not show any specific
alteration. However, we still could not exclude
the possibility that the secondary leukemia arose
in this patient may be part of a cancer-risk
syndrome involving breast cancer, and possibly
a general cancer susceptibility. To the best of
our knowledge, this is the first case to be
reported in the Indonesian subjects as per the
Medline search.
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